Carlos Torrado, MD, MS
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Investigational Cancer Therapeutics, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Sarcoma Medical Oncology, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2021 | CEU Cardenal Herrera University, Castellon, ES, Data Science, Master's Degree in Precision Oncology: Genomics and Big Data in Oncology |
| 2011 | University of Navarra, Pamplona, ES, Medicine, Medical Degree |
Postgraduate Training
| 2024-2024 | Research Fellow, Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP), National Cancer Institute (NCI), Rockville, MD |
| 2024-2025 | Research Fellow, Institute for Data Science in Oncology (IDSO), The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2023-2025 | Clinical Fellow, Investigational Cancer Therapeutics (Phase I), The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2023 | Resident, Medical Oncology, Virgen del Rocio University Hospital, Sevilla, Spain |
Licenses & Certifications
| 2025 | Texas Medical License |
| 2023 | European Society for Mecical Oncology (ESMO)Certification |
| 2018 | Colegio Oficial de Médicos de Sevilla, Spain |
Experience & Service
Administrative Appointments/Responsibilities
Student Council Member, University of Navarra, Pamplona, 2009 - 2011
Selected Publications
Peer-Reviewed Articles
- Rodon J, O'Neil B, Lim C, Ammakkanavar NR, Torrado C, Matsuoka K, Hirai H, Miura A, Anderson B, Jin L, Hangai N, Long A, Wacheck V, Rosen L. Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer. Invest New Drugs, 2026. e-Pub 2026. PMID: 42149426.
- Torrado Martin, C, Andersen, C, Kang, L, Brink, AL, Adesoye, T, Le, H, Patterson, CJ, Poullard, A, Osburn, JA, Tan, HN, Gouda, M, Charles, S, Urschel, G, Tang, T, Hong, DS, Champiat, S, Naing, A, Tsimberidou, AM, Dumbrava, EE, Piha-Paul, SA, Rodon Ahnert, J, Yap, TA, Pohlmann, PR, Meric-Bernstam, F, Fu, S. Telemedicine as a gateway to early-phase oncology trials. Oncologist 31(4), 2026. e-Pub 2026. PMID: 41830429.
- Ngoi NYL, Silverman IM, Johnson A, Meng C, Schonhoft JD, Zimmermann M, Ulanet D, Kim H, Torrado C, Salguero C, Brown CV, Rodon J, Rimkunas V, Koehler M, Yap TA. Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma. NPJ Precis Oncol 9(1):227, 2025. e-Pub 2025. PMID: 40624157.
- Ahmed J, Knisely A, Torrado C, Stephen B, Yang Y, Song J, Alshawa A, Zarifa A, Jhingran A, Koay EJ, Morris VK, Javle M, Wolff RA, Meric-Bernstam F, Pant S, Rodon J, Naing A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
- Torrado C, Feng J, Faour E, Leighl NB. Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report. JTO Clin Res Rep 5(4):100647, 2024. e-Pub 2024. PMID: 38550296.
- Torrado C, Baysal MA, Chakraborty A, Norris BL, Khawaja F, Tsimberidou AM. Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy. Front Immunol 15:1366271, 2024. e-Pub 2024. PMID: 38779675.
- Rhee JY, Garralda E, Torrado C, Blanco S, Ayala I, Namisango E, Luyirika E, de Lima L, Powell RA, Centeno C. Palliative care in Africa: a scoping review from 2005-16. Lancet Oncol 18(9):e522-e531, 2017. e-Pub 2017. PMID: 28884701.
Review Articles
- Torrado C, Gonzalez-Ortiz A, Xavier CB, Tan HN, Ngoi NYL, Yap TA. Drugging the DNA damage response in the clinic: going beyond PARP. Expert Rev Anticancer Ther:1-16, 2025. e-Pub 2025. PMID: 41086259.
- Torrado C, Ashton NW, D'Andrea AD, Yap TA. USP1 inhibition: A journey from target discovery to clinical translation. Pharmacol Ther 271:108865, 2025. e-Pub 2025. PMID: 40274197.
- Torrado C, Nassif Haddad E, Somaiah N, Msaouel P, Lazar AJ, Piha-Paul SA. Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases. J Immunother Precis Oncol 8(2):113-120, 2025. e-Pub 2025. PMID: 40070529.
- Ngoi NYL, Gallo D, Torrado C, Nardo M, Durocher D, Yap TA. Synthetic lethal strategies for the development of cancer therapeutics. Nat Rev Clin Oncol 22(1):46-64, 2025. e-Pub 2025. PMID: 39627502.
- Lopes CDH, Braganca Xavier C, Torrado C, Veneziani AC, Megid TBC. A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives. J Immunother Precis Oncol 7(4):283-299, 2024. e-Pub 2024. PMID: 39524466.
- Ahmed J, Torrado C, Chelariu A, Kim SH, Ahnert JR. Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine. JCO Precis Oncol 8:e2400038, 2024. e-Pub 2024. PMID: 38986029.
- Martinez-Perez J, Torrado C, Dominguez-Cejudo MA, Valladares-Ayerbes M. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer. Int J Mol Sci 25(11), 2024. e-Pub 2024. PMID: 38892410.
- Torrado Martin, C, Camaño, M, Hindi, N, Ortega, J, Sevillano, AR, Civantos, G, Moura, DS, Dimino, A, Martin-Broto, J. Antiangiogenics in Malignant Granular Cell Tumors. Cancers 15(21), 2023. e-Pub 2023. PMID: 37958362.
- Torrado C, Camano M, Hindi N, Ortega J, Sevillano AR, Civantos G, Moura DS, Dimino A, Martin-Broto J. Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature. Cancers (Basel) 15(21), 2023. e-Pub 2023. PMID: 37958362.
- Rhee JY, Garralda E, Torrado C, Blanco S, Ayala I, Namisango E, Luyirika E, de Lima L, Powell RA, Lopez-Fidalgo J, Centeno C. Publications on Palliative Care Development Can Be Used as an Indicator of Palliative Care Development in Africa. J Palliat Med 20(12):1372-1377, 2017. e-Pub 2017. PMID: 28661713.
Editorials
- Torrado C, Plummer R, Yap TA. Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications. JCO Precis Oncol 8:e2400204, 2024. PMID: 38865670.
Book Chapters
- Torrado Martin, C, Tan, HN, Yap, TA. Targeting DNA damage response pathways in cancer, Vol4:186-Vol4:233, 2026.
Patient Reviews
CV information above last modified July 22, 2026